Display options
Cite
Yayoi E, Takatsuka Y, Maeura Y, et al. Comparison of response to 5'-deoxy-5-fluorouridine therapy alone and in combination with tamoxifen or medroxyprogesterone acetate in advanced and recurrent breast-cancer. Int J Oncol. 1994;5(1):27-32doi: 10.3892/ijo.5.1.27.
Yayoi, E., Takatsuka, Y., Maeura, Y., Kotsuma, Y., Kobayashi, T., Aikawa, T., Hirai, T., Kaji, M., Kitada, M., & Tatsuta, M. (1994). Comparison of response to 5'-deoxy-5-fluorouridine therapy alone and in combination with tamoxifen or medroxyprogesterone acetate in advanced and recurrent breast-cancer. International journal of oncology, 5(1), 27-32. https://doi.org/10.3892/ijo.5.1.27
Yayoi, E, et al. "Comparison of response to 5'-deoxy-5-fluorouridine therapy alone and in combination with tamoxifen or medroxyprogesterone acetate in advanced and recurrent breast-cancer." International journal of oncology vol. 5,1 (1994): 27-32. doi: https://doi.org/10.3892/ijo.5.1.27
Yayoi E, Takatsuka Y, Maeura Y, Kotsuma Y, Kobayashi T, Aikawa T, Hirai T, Kaji M, Kitada M, Tatsuta M. Comparison of response to 5'-deoxy-5-fluorouridine therapy alone and in combination with tamoxifen or medroxyprogesterone acetate in advanced and recurrent breast-cancer. Int J Oncol. 1994 Jul;5(1):27-32. doi: 10.3892/ijo.5.1.27. PMID: 21559553.
Copy Download .nbib Format: NLM
Share it on

Int J Oncol. 1994 Jul;5(1):27-32. doi: 10.3892/ijo.5.1.27.

Comparison of response to 5'-deoxy-5-fluorouridine therapy alone and in combination with tamoxifen or medroxyprogesterone acetate in advanced and recurrent breast-cancer.

International journal of oncology

E Yayoi, Y Takatsuka, Y Maeura, Y Kotsuma, T Kobayashi, T Aikawa, T Hirai, M Kaji, M Kitada, M Tatsuta

Affiliations

  1. SHIN SENRI HOSP,DEPT SURG,SUITA,OSAKA,JAPAN. NISHINOMIYA MUNICIPAL CENT HOSP,DEPT SURG,NISHINOMIYA,HYOGO,JAPAN. KANSAI ROUSAI HOSP,DEPT SURG,AMAGASAKI,HYOGO,JAPAN. SAKAI CITY HOSP,DEPT SURG,NISHI SAKAI CITY,OSAKA,JAPAN. OSAKA NATL HOSP,DEPT SURG,CHUO KU,OSAKA,JAPAN. KOTSUMA CLIN,IZUMISANO CITY,OSAKA,JAPAN. OSAKA UNIV,SCH MED,DEPT SURG 2,SUITA,OSAKA 565,JAPAN. HYOGO PREFECTURAL NISHINOMIYA HOSP,DEPT SURG,NISHINOMIYA,HYOGO,JAPAN. TOYONAKA CITY HOSP,DEPT SURG,TOYONAKA,OSAKA,JAPAN.

PMID: 21559553 DOI: 10.3892/ijo.5.1.27

Abstract

We studied the therapeutic usefulness of low dose 5'-deoxy-5-fluorouridine (5'-DFUR) alone and in combination with medroxyprogesterone acetate (MPA) or tamoxifen (TAM). As first line therapy, 58 patients with advanced and recurrent breast cancer were assigned to receive Regimen A (5'-DFUR 600 mg/body/day daily + TAM 30 mg/body/day daily), Regimen B (5'-DFUR 600 mg/body/day daily + MPA 600 mg/body/day daily), or Regimen C (5'-DFUR 600 mg/body/day daily). In 48 evaluable patients, the response rates to treatment were 22.2% (4/18 cases) with Regimen A, 62.5% (10/16 cases) with Regimen B, and 21.4% (3/14 cases) with Regimen C. Regimen B was significantly superior to the other two regimens. The incidence of adverse reactions was low in all three groups, being 10.5% (2/19 cases) with Regimen A, 12.5% (2/16 cases) with Regimen B, and 21.4% (3/14 cases) with Regimen C. In addition, the degree of all adverse reactions was mild (WHO grade 1). Low dose 5'-DFUR therapy in combination with low dose MPA was evaluated to be a useful treatment regimen, emphasizing the quality of life of patients, based on its high effectiveness and safety in advanced and recurrent breast cancer patients.

Publication Types